|
|
Article: Amber Salzman Named President and CEO of Cardiokine.
- Article from:
- Biotech Week
- Article date:
- October 21, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cardiokine, Inc., a privately-held specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of cardiovascular diseases, announced that Amber Salzman, Ph.D., has been named President and Chief Executive Officer and a member of the Board of Directors (see also Cardiokine, Inc.).
"Amber's record of accomplishment and her passion to develop new medications for patients in need make her particularly well suited to lead Cardiokine during this next promising period in the company's history," said James H. Cavanaugh, Ph.D., Chairman of the Board. "Her operational expertise will ensure the timely completion of the ...